{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T21:18:16Z","timestamp":1778275096287,"version":"3.51.4"},"reference-count":63,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.ecl.2017.01.009","type":"journal-article","created":{"date-parts":[[2017,3,8]],"date-time":"2017-03-08T22:01:44Z","timestamp":1489010504000},"page":"459-489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Genetics of Pheochromocytomas and Paragangliomas"],"prefix":"10.1016","volume":"46","author":[{"given":"Rodrigo Almeida","family":"Toledo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ecl.2017.01.009_bib1","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/onc.2015.172","article-title":"Rethinking pheochromocytomas and paragangliomas from a genomic perspective","volume":"35","author":"Castro-Vega","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.ecl.2017.01.009_bib2","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1038\/ncomms7140","article-title":"Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas","volume":"6","author":"Fishbein","year":"2015","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.ecl.2017.01.009_bib3","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/jmedgenet-2015-103218","article-title":"Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients","volume":"52","author":"Curr\u00e1s-Freixes","year":"2015","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.ecl.2017.01.009_bib4","doi-asserted-by":"crossref","first-page":"138573","DOI":"10.1155\/2015\/138573","article-title":"Profiling of somatic mutations in phaeochromocytoma and paraganglioma by targeted next generation sequencing analysis","volume":"2015","author":"Luchetti","year":"2015","journal-title":"Int J Endocrinol"},{"issue":"25","key":"10.1016\/j.ecl.2017.01.009_bib5","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1056\/NEJMoa0806277","article-title":"PHD2 mutation and congenital erythrocytosis with paraganglioma","volume":"359","author":"Ladroue","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ecl.2017.01.009_bib6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00109-014-1205-7","article-title":"Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma\/paraganglioma-polycythemia","volume":"93","author":"Yang","year":"2015","journal-title":"J\u00a0Mol Med (Berl)"},{"issue":"10","key":"10.1016\/j.ecl.2017.01.009_bib7","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/ng.2764","article-title":"The Cancer Genome Atlas Pan-Cancer analysis project","volume":"45","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nat Genet"},{"issue":"11","key":"10.1016\/j.ecl.2017.01.009_bib8","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/hmg\/ddt069","article-title":"Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis","volume":"22","author":"Comino-M\u00e9ndez","year":"2013","journal-title":"Hum Mol Genet"},{"issue":"3","key":"10.1016\/j.ecl.2017.01.009_bib9","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1530\/ERC-13-0101","article-title":"In\u00a0vivo and in\u00a0vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas","volume":"20","author":"Toledo","year":"2013","journal-title":"Endocr Relat Cancer"},{"issue":"9","key":"10.1016\/j.ecl.2017.01.009_bib10","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1093\/hmg\/ddt639","article-title":"Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas","volume":"23","author":"Castro-Vega","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ecl.2017.01.009_bib11","doi-asserted-by":"crossref","first-page":"138573","DOI":"10.1155\/2015\/138573","article-title":"Profiling of somatic mutations in phaeochromocytoma and paraganglioma by targeted next generation sequencing analysis","volume":"2015","author":"Luchetti","year":"2015","journal-title":"Int J Endocrinol"},{"issue":"7","key":"10.1016\/j.ecl.2017.01.009_bib12","doi-asserted-by":"crossref","first-page":"E1376","DOI":"10.1210\/jc.2013-3879","article-title":"H-RAS mutations are restricted to sporadic pheochromocytomas lacking specific clinical or pathological features: data from a multi-institutional series","volume":"99","author":"Oudijk","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ecl.2017.01.009_bib13","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/gcc.22347","article-title":"HRAS mutation prevalence and associated expression patterns in pheochromocytoma","volume":"55","author":"Stenman","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"10.1016\/j.ecl.2017.01.009_bib14","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1210\/jc.2009-2170","article-title":"Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas","volume":"95","author":"Gaal","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.ecl.2017.01.009_bib15","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1101\/gad.1648608","article-title":"The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor","volume":"22","author":"Schlisio","year":"2008","journal-title":"Genes Dev"},{"issue":"3","key":"10.1016\/j.ecl.2017.01.009_bib16","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00439-008-0553-1","article-title":"A\u00a0germline mutation of the KIF1B beta gene on 1p36 in a family with neural and nonneural tumors","volume":"124","author":"Yeh","year":"2008","journal-title":"Hum Genet"},{"issue":"9","key":"10.1016\/j.ecl.2017.01.009_bib17","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/gcc.22267","article-title":"Whole-exome sequencing defines the mutational landscape of pheochromocytoma and identifies KMT2D as a recurrently mutated gene","volume":"54","author":"Juhlin","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"issue":"10","key":"10.1016\/j.ecl.2017.01.009_bib18","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1158\/1078-0432.CCR-12-0160","article-title":"MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma","volume":"18","author":"Burnichon","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"7492","key":"10.1016\/j.ecl.2017.01.009_bib19","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ecl.2017.01.009_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv053","article-title":"Whole-exome sequencing identifies MDH2 as a new familial paraganglioma gene","volume":"107","author":"Casc\u00f3n","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.ecl.2017.01.009_bib21","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1002\/ijc.29957","article-title":"Malignant pheochromocytomas\/paragangliomas harbor mutations in transport and cell adhesion genes","volume":"138","author":"Wilz\u00e9n","year":"2016","journal-title":"Int J Cancer"},{"issue":"26","key":"10.1016\/j.ecl.2017.01.009_bib22","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1093\/hmg\/dds374","article-title":"Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma","volume":"21","author":"Burnichon","year":"2012","journal-title":"Hum Mol Genet"},{"issue":"20","key":"10.1016\/j.ecl.2017.01.009_bib23","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1093\/hmg\/ddr324","article-title":"Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma","volume":"20","author":"Burnichon","year":"2011","journal-title":"Hum Mol Genet"},{"issue":"8","key":"10.1016\/j.ecl.2017.01.009_bib24","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1210\/jc.2008-2504","article-title":"The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas","volume":"94","author":"Burnichon","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2017.01.009_bib25","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1210\/jc.2015-3856","article-title":"Epigenetic mutation of the succinate dehydrogenase C promoter in a patient with two paragangliomas","volume":"101","author":"Richter","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"23","key":"10.1016\/j.ecl.2017.01.009_bib26","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1001\/jama.2010.1830","article-title":"Spectrum and prevalence of FP\/TMEM127 gene mutations in pheochromocytomas and paragangliomas","volume":"304","author":"Yao","year":"2010","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ecl.2017.01.009_bib27","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrc3648","article-title":"Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity","volume":"14","author":"Dahia","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.ecl.2017.01.009_bib28","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrendo.2014.188","article-title":"Paraganglioma and phaeochromocytoma: from genetics to personalized medicine","volume":"11","author":"Favier","year":"2015","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"10.1016\/j.ecl.2017.01.009_bib29","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1093\/hmg\/ddw057","article-title":"Germline ESR2 mutation predisposes to medullary thyroid carcinoma and causes up-regulation of RET expression","volume":"25","author":"Smith","year":"2016","journal-title":"Hum Mol Genet"},{"issue":"9","key":"10.1016\/j.ecl.2017.01.009_bib30","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1158\/1078-0432.CCR-15-1841","article-title":"Recurrent mutations of chromatin-remodeling genes and kinase receptors in pheochromocytomas and paragangliomas","volume":"22","author":"Toledo","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ecl.2017.01.009_bib31","first-page":"647","article-title":"Cloning and mRNA expression analysis of a novel human protooncogene, c-mer","volume":"5","author":"Graham","year":"1994","journal-title":"Cell Growth Differ"},{"issue":"7","key":"10.1016\/j.ecl.2017.01.009_bib32","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1210\/jc.2004-0073","article-title":"A\u00a0novel point mutation of the RET protooncogene involving the second intracellular tyrosine kinase domain in a family with medullary thyroid carcinoma","volume":"89","author":"Jimenez","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2017.01.009_bib33","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood-2006-05-021634","article-title":"A\u00a0soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation","volume":"109","author":"Sather","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ecl.2017.01.009_bib34","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.cell.2007.10.034","article-title":"TAM receptors are pleiotropic inhibitors of the innate immune response","volume":"131","author":"Rothlin","year":"2007","journal-title":"Cell."},{"issue":"3","key":"10.1016\/j.ecl.2017.01.009_bib35","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1083\/jcb.49.3.664","article-title":"The role of the pigment epithelium in the etiology of inherited retinal dystrophy in the rat","volume":"49","author":"Bok","year":"1971","journal-title":"J\u00a0Cell Biol."},{"issue":"3","key":"10.1016\/j.ecl.2017.01.009_bib36","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/81555","article-title":"Mutations in MERTK, the human orthologue of the RCS rat retinal dystrophy gene, cause retinitis pigmentosa","volume":"26","author":"Gal","year":"2000","journal-title":"Nat Genet"},{"issue":"45","key":"10.1016\/j.ecl.2017.01.009_bib37","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1038\/sj.onc.1209633","article-title":"Lymphoblastic leukemia\/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase","volume":"25","author":"Keating","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.ecl.2017.01.009_bib38","series-title":"Genetic alterations in pheochromocytoma and paraganglioma","first-page":"64","author":"Welander","year":"2015"},{"issue":"1","key":"10.1016\/j.ecl.2017.01.009_bib39","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/cen.12357","article-title":"Next-generation sequencing for the genetic screening of phaeochromcytomas and paragangliomas: riding the new wave, but with caution","volume":"80","author":"Toledo","year":"2014","journal-title":"Clin Endocrinol (oxf)"},{"issue":"8","key":"10.1016\/j.ecl.2017.01.009_bib40","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/ng.2682","article-title":"Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma","volume":"45","author":"Jones","year":"2013","journal-title":"Nat Genet"},{"issue":"25","key":"10.1016\/j.ecl.2017.01.009_bib41","doi-asserted-by":"crossref","first-page":"8713","DOI":"10.1073\/pnas.0803379105","article-title":"Drug-sensitive FGFR2 mutations in endometrial carcinoma","volume":"105","author":"Dutt","year":"2008","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"7","key":"10.1016\/j.ecl.2017.01.009_bib42","doi-asserted-by":"crossref","first-page":"E1352","DOI":"10.1210\/jc.2013-4375","article-title":"Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma","volume":"99","author":"Welander","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"25","key":"10.1016\/j.ecl.2017.01.009_bib43","doi-asserted-by":"crossref","first-page":"6837","DOI":"10.1182\/blood-2010-07-295725","article-title":"Constitutive Notch pathway activation in murine ZMYM2-FGFR1-induced T-cell lymphomas associated with atypical myeloproliferative disease","volume":"117","author":"Ren","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ecl.2017.01.009_bib44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/ijmm.2016.2620","article-title":"FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis (review)","volume":"38","author":"Katoh","year":"2016","journal-title":"Int J Mol Med"},{"issue":"2","key":"10.1016\/j.ecl.2017.01.009_bib45","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/(SICI)1098-1004(1999)14:2<115::AID-HUMU3>3.0.CO;2-2","article-title":"Clinical spectrum of fibroblast growth factor receptor mutations","volume":"14","author":"Passos-Bueno","year":"1999","journal-title":"Hum Mutat"},{"issue":"3","key":"10.1016\/j.ecl.2017.01.009_bib46","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ajhg.2016.02.006","article-title":"Mosaic activating mutations in FGFR1 cause encephalocraniocutaneous lipomatosis","volume":"98","author":"Bennett","year":"2016","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ecl.2017.01.009_bib47","doi-asserted-by":"crossref","first-page":"7877","DOI":"10.1038\/ncomms8877","article-title":"Structural and dynamic insights into the energetics of activation loop rearrangement in FGFR1 kinase","volume":"6","author":"Klein","year":"2015","journal-title":"Nat Commun"},{"issue":"6046","key":"10.1016\/j.ecl.2017.01.009_bib48","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/318533a0","article-title":"The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice","volume":"318","author":"Adams","year":"1985","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ecl.2017.01.009_bib49","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/sj.bjc.6601894","article-title":"The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website","volume":"91","author":"Bamford","year":"2004","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.ecl.2017.01.009_bib50","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ng.861","article-title":"Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma","volume":"43","author":"Comino-M\u00e9ndez","year":"2011","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.ecl.2017.01.009_bib51","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1158\/2159-8290.CD-12-0426","article-title":"Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN","volume":"3","author":"Bjerke","year":"2013","journal-title":"Cancer Discov"},{"issue":"7384","key":"10.1016\/j.ecl.2017.01.009_bib52","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature10833","article-title":"Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma","volume":"482","author":"Schwartzentruber","year":"2012","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.ecl.2017.01.009_bib53","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/ng.2814","article-title":"Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone","volume":"45","author":"Behjati","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.ecl.2017.01.009_bib54","doi-asserted-by":"crossref","first-page":"11185","DOI":"10.1038\/ncomms11185","article-title":"Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma","volume":"7","author":"Nikbakht","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.ecl.2017.01.009_bib55","doi-asserted-by":"crossref","first-page":"6044","DOI":"10.1038\/ncomms7044","article-title":"Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas","volume":"6","author":"Castro-Vega","year":"2015","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.ecl.2017.01.009_bib56","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.ecl.2017.01.009_bib57","first-page":"389","article-title":"Targeting MET in NSCLC: looking for a needle in a haystack","volume":"3","author":"Landi","year":"2014","journal-title":"Transl Lung Cancer Res"},{"issue":"5","key":"10.1016\/j.ecl.2017.01.009_bib58","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nri2303","article-title":"Immunobiology of the TAM receptors","volume":"8","author":"Lemke","year":"2008","journal-title":"Nat Rev Immunol"},{"issue":"5528","key":"10.1016\/j.ecl.2017.01.009_bib59","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1126\/science.1061663","article-title":"Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family","volume":"293","author":"Lu","year":"2001","journal-title":"Science"},{"issue":"30","key":"10.1016\/j.ecl.2017.01.009_bib60","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1200\/JCO.2014.60.7341","article-title":"Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors","volume":"33","author":"Tabernero","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.ecl.2017.01.009_bib61","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1172\/JCI67816","article-title":"MERTK receptor tyrosine kinase is a therapeutic target in melanoma","volume":"123","author":"Schlegel","year":"2013","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"10.1016\/j.ecl.2017.01.009_bib62","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1470-2045(10)70007-3","article-title":"SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma","volume":"11","author":"Bayley","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ecl.2017.01.009_bib63","article-title":"Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas","author":"NGS in PPGL (NGSnPPGL) Study Group","year":"2016","journal-title":"Nat Rev Endocrinol"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852917300099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852917300099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:42:28Z","timestamp":1760175748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852917300099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0889852917300099"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2017.01.009","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetics of Pheochromocytomas and Paragangliomas","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2017.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}